Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
作者信息
Rundquist Sara, Sachs Michael C, Eriksson Carl, Olén Ola, Montgomery Scott, Halfvarson Jonas
机构信息
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
出版信息
Aliment Pharmacol Ther. 2021 May;53(9):1046-1047. doi: 10.1111/apt.16352.
PMID:33831234
Abstract
摘要
Zotero 插件